Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Combined With Chemo-Immunotherapy in Metastatic NSCLC Patients With Weight Loss
NCT07889232Phase 2Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Nov 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in non-small cell lung cancer (NSCLC), sponsored by VA Office of Research & Development. Primary endpoints: Safety of adding Tocilizumab to Standard of Care Immunotherapy at 12 weeks, Progression-Free Survival Rate at 6 months and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07889232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07889232.